证券代码：300550 证券简称：和仁科技 公告编号：2025-023 浙江和仁科技股份有限公司 特此公告。 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 二、监事会会议审议情况 经与会监事审议并在议案表决票上签字表决，审议通过如下议案： 浙江和仁科技股份有限公司（以下简称"公司"）第四届监事会第十次会议 于 2025 年 8 月 19 日在公司会议室以现场结合通讯表决的方式召开。 1、审议通过《关于公司 2025 年半年度报告全文及摘要的议案》 召开本次会议的通知已于 2025 年 8 月 8 日以电子邮件方式通知各位监事。 会议应参与表决监事 3 名，实际参与会议表决监事 3 名，监事陶朦朦女士以通讯 形式参与会议，其余监事现场参与会议。此次会议达到法定人数，符合《公司法》 和《公司章程》的规定。 表决结果： 3 票同意，0 票反对，0 票弃权 经审核，监事会认为："董事会编制和审核浙江和仁科技股份有限公司 2025 年半年度报告的程序符合法律、行政法规和中国证券监督管理委员会的规定，报 告内容真实 ...

证券代码：300550 证券简称：和仁科技 公告编号：2025-022 浙江和仁科技股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江和仁科技股份有限公司（以下简称"公司"）第四届董事会第十一次会 议于 2025 年 8 月 19 日以现场表决结合通讯表决方式召开。 召开本次会议的通知已于 2025 年 8 月 8 日以电子邮件形式送达各位董事。 本次董事会会议应参与表决董事 7 名，实际参与表决董事 7 名。会议由董事长赵 晨晖先生主持，独立董事蔡钰如女士以通讯形式参与会议，其他董事以现场形式 参与会议，监事以及高级管理人员列席会议。本次会议的召集、召开及表决程序 符合《公司法》等法律、法规、规范性文件以及《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议并在议案表决票上签字表决，审议通过如下议案： 1、审议通过《关于公司 2025 年半年度报告全文及摘要的议案》 表决结果：7 票同意，0 票反对，0 票弃权 本议案已经公司审计委员会审议通过。 《 2025 年 半 年度 ...

格隆汇8月20日丨和仁科技(300550.SZ)公布2025年半年度报告，上半年公司实现营业收入1.59亿元，同 比下降0.99%；归属于上市公司股东的净利润-351.998万元；归属于上市公司股东的扣除非经常性损益 的净利润-441.32万元；基本每股收益-0.01元。 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=第一节%20重要提示、目录和释义) [Important Notice and Risk Disclosure](index=2&type=section&id=重要提示与风险披露) Management confirms the report's accuracy, cautions on macroeconomic, policy, and accounts receivable risks, and states no profit distribution is planned - The company faces five major operating risks: - **Large-scale system solution implementation risks**: High project complexity and long implementation cycles may lead to delays due to planning flaws, technical failures, or changing client demands - **Major customer loss risks**: High customer concentration among large and medium-sized medical institutions means client loss would significantly impact sustainable development - **Management control and gross margin fluctuation risks**: Expanding business scope demands higher project management control, while overall solution business may reduce comprehensive gross margin - **Technology and talent loss risks**: As a technology-intensive industry, the stability of the core technical team is crucial, with risks of talent outflow and core technology leakage - **National policy and macroeconomic environment change risks**: National healthcare informatization policies offer industry opportunities, but significant policy or macroeconomic changes could introduce operational uncertainties[5](index=5&type=chunk)[7](index=7&type=chunk)[8](index=8&type=chunk)[10](index=10&type=chunk)[11](index=11&type=chunk) - The company plans **not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital**[13](index=13&type=chunk) [Definitions](index=8&type=section&id=释义) This section defines key terms, including company entities, industry-specific systems like HIS and CIS, the 'Digital Hospital Overall Solution,' and specifies the reporting period as H1 2025 [Company Profile and Key Financial Indicators](index=10&type=section&id=第二节%20公司简介和主要财务指标) [Company Profile](index=10&type=section&id=公司简介) Zhejiang Horen Technology Co., Ltd. (stock code: 300550), listed on the Shenzhen Stock Exchange, is represented by Zhao Chenhui, with no changes in registered address, office address, or information disclosure locations during the reporting period Company Basic Information | Item | Content | | :--- | :--- | | Stock Abbreviation | Horen Technology | | Stock Code | 300550 | | Listing Exchange | Shenzhen Stock Exchange | | Company Full Chinese Name | 浙江和仁科技股份有限公司 | | Legal Representative | Zhao Chenhui | [Key Accounting Data and Financial Indicators](index=11&type=section&id=主要会计数据和财务指标) In H1 2025, despite nearly flat revenue, the company significantly narrowed its net loss and improved operating cash flow, indicating an overall improvement in financial performance Key Financial Indicators for H1 2025 | Indicator | Current Period | Prior Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (million yuan) | 158.88 | 160.46 | -0.99% | | Net Profit Attributable to Shareholders (million yuan) | -3.52 | -14.33 | 75.44% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) (million yuan) | -4.41 | -15.98 | 72.38% | | Net Cash Flow from Operating Activities (million yuan) | -64.99 | -96.29 | 32.50% | | Basic Earnings Per Share (yuan/share) | -0.01 | -0.05 | 80.00% | | Weighted Average Return on Net Assets | -0.32% | -1.34% | 1.02% | Key Balance Sheet Indicators at Period End | Indicator | End of Current Period (billion yuan) | End of Prior Year (billion yuan) | Change from Beginning of Year | | :--- | :--- | :--- | :--- | | Total Assets | 1.44 | 1.46 | -1.56% | | Net Assets Attributable to Shareholders | 1.10 | 1.11 | -0.91% | - During the reporting period, the company's total non-recurring gains and losses amounted to **0.89 million yuan**, primarily from fair value changes in financial assets and government subsidies[33](index=33&type=chunk) [Management Discussion and Analysis](index=13&type=section&id=第三节%20管理层讨论与分析) [Main Business Activities During the Reporting Period](index=13&type=section&id=报告期内公司从事的主要业务) The company's core business involves R&D, sales, implementation, and service of medical information and digital scenario application systems, offering overall solutions to healthcare institutions, driven by national policies and AI advancements - The company's main business is divided into two segments: **Medical Information Systems** (including hospital clinical information systems centered on electronic medical records and city-level smart healthcare solutions) and **Digital Scenario Application Systems** (extensions of clinical information systems in various medical service scenarios, such as smart outpatient and smart surgery)[36](index=36&type=chunk)[37](index=37&type=chunk)[39](index=39&type=chunk) - The company's products support **domestic operating systems and databases** and feature **modular component assembly**, enhancing productization, meeting personalized needs, and reducing development costs[42](index=42&type=chunk)[43](index=43&type=chunk) - During the reporting period, the National Health Commission issued policies like the **'Smart Healthcare Grading Evaluation Method and Standards (2025 Edition)'** and **'Tier-3 Hospital Review Standards (2025 Edition)'**, emphasizing data interoperability, AI applications, and medical quality, providing clear guidance and market drivers for industry development[48](index=48&type=chunk)[49](index=49&type=chunk)[51](index=51&type=chunk) [Analysis of Core Competencies](index=17&type=section&id=核心竞争力分析) The company's core competencies include comprehensive solution capabilities based on proprietary clinical products, advanced technology, continuous innovation, full lifecycle services, premium client resources, and an experienced management and talent team - The company provides **top-down designed, hospital-wide smart hospital overall solutions** centered on clinical data interoperability, occupying a core position in medical informatization construction[58](index=58&type=chunk)[59](index=59&type=chunk) - The company's new-generation hospital information system is one of China's **largest core business systems based on HTML5 and cloud computing technology**, supporting cloud deployment, group hospital applications, and integrating HIS with EMR[62](index=62&type=chunk) - The company has established **long-term partnerships with top-tier large medical institutions** in military systems and multiple regions like Zhejiang, Jiangsu, Jiangxi, and Shaanxi, accumulating extensive successful cases and implementation experience[64](index=64&type=chunk) [Analysis of Main Business Operations](index=19&type=section&id=主营业务分析) During the reporting period, operating revenue slightly decreased, but a significant drop in operating costs boosted gross margin, while R&D investment substantially increased; medical information systems dominated revenue with improved gross margin, and regional performance varied, with strong growth in Central China Key Financial Data Year-on-Year Changes | Item | Current Period (million yuan) | Prior Period (million yuan) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Cost | 89.92 | 112.59 | -20.14% | - | | Financial Expenses | -2.15 | -3.09 | 30.51% | Primarily due to decreased interest income | | R&D Investment | 31.72 | 23.63 | 34.27% | Primarily due to increased R&D investment in this period | | Net Cash Flow from Investing Activities | -40.74 | 9.98 | -508.22% | Primarily due to increased purchase of wealth management products | | Net Cash Flow from Financing Activities | -33.56 | -0.95 | -3,431.93% | Primarily due to decreased loans compared to the prior period | Operating Revenue by Product or Service (million yuan) | Product/Service | Operating Revenue (million yuan) | Operating Cost (million yuan) | Gross Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Scenario-based Application Systems | 34.05 | 27.18 | 20.18% | -29.01% | -32.01% | 3.53% | | Medical Information Systems | 89.12 | 44.99 | 49.51% | 0.45% | -26.70% | 18.70% | Operating Revenue by Region (million yuan) | Region | Operating Revenue (million yuan) | YoY Change in Operating Revenue | Gross Margin | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | | Northwest Region | 81.77 | -11.10% | 53.98% | 26.81% | | East China Region | 37.73 | -39.49% | 41.60% | 8.08% | | Central China Region | 26.93 | 1,699.45% | 11.22% | -29.08% | [Analysis of Assets and Liabilities](index=21&type=section&id=资产及负债状况分析) At period-end, total assets decreased, with a notable shift in asset structure as cash declined and contract assets rose, while short-term borrowings decreased, and some cash remained restricted due to guarantees and litigation Significant Changes in Asset Composition | Item | Proportion of Total Assets at Period End | Proportion of Total Assets at Beginning of Year | Change in Proportion | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 28.05% | 37.08% | -9.03% | | Accounts Receivable | 22.08% | 20.66% | 1.42% | | Contract Assets | 25.59% | 20.71% | 4.88% | | Short-term Borrowings | 4.87% | 6.57% | -1.70% | - As of the end of the reporting period, **4.62 million yuan** of the company's cash and cash equivalents were restricted, primarily for bill deposits, letter of guarantee deposits, migrant worker wage guarantees, and litigation-frozen funds[81](index=81&type=chunk)[491](index=491&type=chunk) [Analysis of Investment Activities](index=22&type=section&id=投资状况分析) During the reporting period, the company's investment increased, primarily in wealth management products using own funds, with no significant equity, non-equity, or derivative investments Overview of Entrusted Wealth Management (million yuan) | Specific Type | Source of Funds for Entrusted Wealth Management | Amount of Entrusted Wealth Management Occurred (million yuan) | Unmatured Balance (million yuan) | | :--- | :--- | :--- | :--- | | Bank Wealth Management Products | Own Funds | 60 | 30 | [Analysis of Major Holding and Participating Companies](index=24&type=section&id=主要控股参股公司分析) The company established new subsidiaries and deregistered others to expand digital hospital business and enhance operational efficiency, with its main subsidiary, Zhejiang Meihe Institute, reporting a net loss - To accelerate digital hospital business expansion and market layout, the company established **Horen Health Technology Hong Kong Co., Ltd., Nanjing Horen Digital Medical Technology Co., Ltd., Wenzhou Shukangjian Technology Industry Development Co., Ltd., and Wenzhou Shujian Technology Co., Ltd.**[93](index=93&type=chunk)[134](index=134&type=chunk) - Due to business strategy adjustments, the company deregistered **Shanghai Horkangyi Technology Co., Ltd.** and established and then deregistered **Zhejiang Hezhong Renxin Technology Co., Ltd.**, neither of which had a substantial impact on operations or performance[93](index=93&type=chunk)[134](index=134&type=chunk) [Corporate Governance, Environment, and Society](index=27&type=section&id=第四节%20公司治理、环境和社会) [Corporate Governance and Social Responsibility](index=27&type=section&id=公司治理与社会责任) During the reporting period, there were no changes in the company's directors, supervisors, or senior management, no profit distribution or equity incentive plans, and the company actively fulfilled its social responsibilities by protecting stakeholder rights - There were **no changes in the company's directors, supervisors, and senior management** during the reporting period[103](index=103&type=chunk) - The company plans **not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital** for the half-year period[104](index=104&type=chunk) - The company actively fulfills its social responsibilities, focusing on **protecting the rights and interests of shareholders, employees, suppliers, and customers**[106](index=106&type=chunk)[107](index=107&type=chunk) [Significant Matters](index=29&type=section&id=第五节%20重要事项) [Litigation and Major Contracts](index=29&type=section&id=诉讼与重大合同) While no major litigation occurred, several other significant cases, including arbitration with PLA General Hospital and a lawsuit with Xi'an Construction Group, are ongoing; the company is also executing major smart hospital projects with Xinjiang TCM Hospital, Xi'an Honghui Hospital, and Xi'an Children's Hospital Other Litigation Matters (Partial) | Litigant | Amount Involved (million yuan) | Litigation Progress | | :--- | :--- | :--- | | Zhejiang Horen Technology vs. PLA General Hospital | 22.26 | Arbitration filed, not yet heard | | Zhejiang Horen Technology vs. Xi'an Construction Engineering Group Co., Ltd. et al. | 16.06 | Case filed, under normal trial | | Shanxi Zhijie Software Engineering Co., Ltd. vs. Zhejiang Horen Technology | 3.34 | Second instance judgment rendered, appeal dismissed, original judgment upheld | | Zhejiang Horen Technology vs. Nantong Yilian E-commerce Co., Ltd. | 2.79 | First instance judgment supported plaintiff, defendant appealed, second instance under trial | Performance of Major Daily Operating Contracts (Partial) | Client Name | Contract Content | Total Contract Amount (million yuan) | Overall Progress | | :--- | :--- | :--- | :--- | | Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine | Smart Hospital Informatization Project | 148.16 | 42.03% | | Xi'an Honghui Hospital | Multi-campus Integrated 'Smart Hospital' Scenario Application Project | 165.87 | 96.87% | | China Construction Eighth Engineering Division Second Construction Co., Ltd. | Xi'an Children's Hospital Jingkai Campus Project Intelligent Engineering | 148.91 | 66.05% | | PLA General Hospital | Subcontract for Low-Voltage Intelligent Engineering of Outpatient and Emergency Comprehensive Building | 141.41 | Accepted but not yet settled | [Share Changes and Shareholder Information](index=36&type=section&id=第六节%20股份变动及股东情况) [Share Changes and Shareholder Information](index=36&type=section&id=股份变动与股东情况) At period-end, the company's total share capital and shareholder count remained stable, with the top three shareholders identified, and the controlling shareholder's shares, along with its concerted parties, partially pledged - During the reporting period, the company's **total share capital remained unchanged at 262,560,141 shares**[137](index=137&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | Tongce Medical Co., Ltd. | 19.01% | 49,920,315 | | Hangzhou Panyuan Investment Co., Ltd. | 15.33% | 40,260,815 | | Xiamen Silicon Valley Shaohua I Investment Partnership | 10.01% | 26,273,850 | | Hangzhou Panhong Investment Management Partnership | 5.42% | 14,240,800 | - Of the shares held by controlling shareholder Hangzhou Panyuan Investment Co., Ltd., **22,282,825 shares are pledged**, representing **55.35%** of its holdings; its concerted party, Hangzhou Panhong Investment Management Partnership (Limited Partnership), has **9,500,000 shares pledged**[139](index=139&type=chunk)[669](index=669&type=chunk) [Bond-Related Information](index=41&type=section&id=第七节%20债券相关情况) [Bond Status](index=41&type=section&id=债券情况) The company had no bond-related information during the reporting period [Financial Report](index=42&type=section&id=第八节%20财务报告) [Financial Statements](index=42&type=section&id=财务报表) This unaudited semi-annual financial report presents the consolidated balance sheet, income statement, and cash flow statement, detailing the company's assets, liabilities, equity, revenue, costs, and cash flows for the period Consolidated Balance Sheet Summary (June 30, 2025) | Item | Period-End Balance (billion yuan) | Beginning-of-Period Balance (billion yuan) | | :--- | :--- | :--- | | Total Assets | 1.44 | 1.46 | | Total Liabilities | 0.33 | 0.34 | | Total Equity Attributable to Parent Company Owners | 1.10 | 1.11 | Consolidated Income Statement Summary (H1 2025) | Item | Current Period Amount (million yuan) | Prior Period Amount (million yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 158.88 | 160.46 | | Total Operating Costs | 150.64 | 168.68 | | Net Profit | -3.68 | -14.56 | | Net Profit Attributable to Parent Company Shareholders | -3.52 | -14.33 | Consolidated Cash Flow Statement Summary (H1 2025) | Item | Current Period Amount (million yuan) | Prior Period Amount (million yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -64.99 | -96.29 | | Net Cash Flow from Investing Activities | -40.74 | 9.98 | | Net Cash Flow from Financing Activities | -33.56 | -0.95 | | Net Increase in Cash and Cash Equivalents | -139.30 | -87.26 | [Notes to Financial Statements](index=60&type=section&id=财务报表附注) The notes detail the company's background, financial statement preparation basis, and significant accounting policies, including revenue recognition, R&D capitalization, and financial instrument impairment, with no major policy changes and tax benefits as a key software enterprise - The company's revenue recognition policy for **digital scenario application system implementation business** is based on the input method according to the progress of performance; for **medical information system software sales and development**, revenue is recognized when the customer confirms and the right to receive payment is obtained[313](index=313&type=chunk)[315](index=315&type=chunk) - R&D expenditure capitalization policy: The company begins capitalization after completing the project design, meeting expected requirements, and passing project approval, ceasing capitalization and transferring to intangible assets upon completion of development into standardized products ready for delivery[296](index=296&type=chunk) - The company enjoys tax incentives, including **immediate refund of VAT exceeding 3% for software products** and a **temporary 10% corporate income tax rate for 2025** as a key software enterprise within national planning[360](index=360&type=chunk)

Group 1 - The stock price of HeRen Technology is 13.40 yuan as of August 15, 2025, with an increase of 0.16 yuan, representing a rise of 1.21% from the previous trading day [1] - The opening price for the day was 13.25 yuan, with a highest point of 13.51 yuan and a lowest point of 13.20 yuan, resulting in a trading volume of 64,100 hands and a transaction amount of 86 million yuan [1] - HeRen Technology operates in the software development industry, focusing on smart healthcare, providing comprehensive hospital information solutions [1] Group 2 - The company's business includes clinical data centers and hospital information system integration, aiming for the standardization and interconnectivity of medical data [1] - HeRen Technology stated on its interactive platform that the clinical data center is a core module of its smart hospital solution, enabling data interconnectivity through an integrated platform with various hospital information systems [1] - On August 15, the net outflow of main funds was 12.32 million yuan, with a cumulative net outflow of 21.01 million yuan over the past five days [1]

每经AI快讯，有投资者在投资者互动平台提问：有在公司官网看到公司有数据中心产品。请介绍一下 公司在数据中心领域的技术应用？ 和仁科技（300550.SZ）8月15日在投资者互动平台表示，临床数据中心是公司的智慧医院整体解决方案 的核心模块之一。公司通过集成平台与HIS（医院信息系统）、PACS（影像存档传输系统）、RIS（放 射信息系统）、LIS（检验信息系统）等众多医院其他信息系统进行数据的实时、双向的互联互通；将 病人分散在各个系统中的数据按照一元化、标准化、结构化的原则进行数据的采集、融合，形成院级临 床数据中心，并统一从数据中心支撑各项数据应用。 （文章来源：每日经济新闻） ...

金融界8月15日消息，有投资者在互动平台向和仁科技提问：尊敬的领导您好！有在公司官网看到公司 有数据中心产品。请介绍一下公司在数据中心领域的技术应用？ 公司回答表示：尊敬的投资者，您好，临床数据中心是公司的智慧医院整体解决方案的核心模块之一。 公司通过集成平台与HIS（医院信息系统）、PACS（影像存档传输系统）、RIS（放射信息系统）、 LIS（检验信息系统）等众多医院其他信息系统进行数据的实时、双向的互联互通；将病人分散在各个 系统中的数据按照一元化、标准化、结构化的原则进行数据的采集、融合，形成院级临床数据中心，并 统一从数据中心支撑各项数据应用。感谢您的关注。 ...

证券之星消息，截至2025年8月13日收盘，和仁科技(300550)报收于13.45元，下跌1.54%，换手率 2.53%，成交量6.64万手，成交额8948.1万元。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-13 | 13.45 | -1.54% | -689.04万 | -7.70% | 1001.34万 | 11.19% | -312.31万 | -3.49% | | 2025-08-12 | 13.66 | -1.09% | -1212.02万 | -21.61% | 252.57万 | 4.50% | 959.45万 | 17.11% | | 2025-08-11 | 13.81 | 2.45% | -689.82万 | -9.19% | -147.36万 | -1.96% | 837.18万 | 11.15% | | 2025-08-08 | 13.48 | -2.53% | -1303 ...

风险提示：股市有风险，投资需谨慎。 来源:金融界 截至2025年8月12日收盘，和仁科技股价报13.66元，较前一交易日下跌1.09%。当日成交额0.56亿元， 换手率1.56%。 和仁科技属于软件开发行业，业务涵盖互联医疗、区块链等领域。公司专注于医疗信息化领域，通过技 术手段整合临床、管理等数据，构建统一的数据中心，助力医院数字化转型。 消息面上，和仁科技在互动平台表示，公司数据中心产品交付效果显著，能够实时支撑临床诊疗，深度 挖掘运营数据，并为科研提供数据支持，全方位助力医院高质量发展。 资金方面，8月12日主力资金净流出1212.02万元，近五日累计净流出3537.43万元。 ...

证券日报网讯 和仁科技8月12日在互动平台回答投资者提问时表示，公司数据中心产品交付效果显著： 实时支撑临床诊疗，保障数据及时可用；深度挖掘运营数据，为管理决策提供精准依据；整合科研相关 数据，加速研究进程。通过整合临床、管理等数据，依托技术保障数据完整、准确、安全，构建全院统 一数据中心，全方位助力医院高质量发展。 （编辑 袁冠琳） ...